Introduction ▼
Chronic diabetic sensorimotor distal symmetric polyneuropathy (DPN) as the most common form of diabetic neuropathy is associated with considerable morbidity, increased mortality and reduced quality of life ( Boulton et al., 2005 ; Tesfaye et al., 2010 ) . There is evidence that the complex interactions between metabolic and vascular factors, in particular nerve ischemia and hypoxia, are major players in the pathogenesis of DPN ). Several therapeutic approaches have been developed based on these mechanisms. They target, however, symptomatic treatment of neuropathic pain ( Chong and Hester, 2007 ) rather than slowing down the disease progression. Moreover, they are associated with central nervous system side eff ects. In a randomized, double-blind, placebo-controlled clinical trial, Actovegin ® was shown to have benefi cial eff ects on the clinical symptoms of 
Abstract ▼
Background: Diabetic neuropathy is one of the most severe complications of diabetes, aff ecting approximately one-third of diabetic patients. We investigated the potential neuroprotective eff ect of Actovegin ® , a deproteinized hemoderivative of calf blood, in an animal model of diabetic neuropathy. Methods: A single intravenous injection of streptozotocin (STZ, 55 mg/kg) was used to induce experimental diabetes in male Sprague-Dawley rats. Actovegin ® (200 or 600 mg/kg) was administered intraperitoneally from day 11 to day 40 post-STZ exposure. N-acetylcysteine (NAC) was used as a positive control and was added to drinking water (0.2 g/l) from day 2 until day 40. Measurements to assess effi cacy included sensory nerve conduction velocity (SNCV), intraepidermal nerve fi ber density (IENFD), and poly(ADP-ribose) content.
Results:
A decrease (35 %) in sensory nerve conduction velocity (SNCV) was seen in STZinduced diabetic rats from day 10 post-STZ administration and persisted at days 25 and 39. At study completion (day 41), a decrease (32 %) in intraepidermal nerve fi ber density (IENFD) was found in hind-paw skin biopsies from STZ-rats. 
Sensory nerve conduction velocity (SNCV) analysis
Electrophysiological recordings were performed on day-3 (baseline) and on days 10, 25 and 39 post-STZ administration, using the method previously described ( 
IENFD analysis
On day 41, rats were anesthetized by i. p. injection of 100 mg/kg ketamine, and a 5-10 mm diameter area of skin was taken from the hind paw. Skin samples were immediately fi xed in 4 % paraformaldehyde at 4 °C, incubated overnight in 30 % sucrose (in 0.1 M phosphate-buff ered saline [PBS]) for cryoprotection, embedded in Tissue-Tek ® OCT ™ Compound and frozen at − 80 °C.
Cryosections (50 μm) were then cut vertically to the skin surface. Free-fl oating sections were incubated for 7 days in a bath of Rabbit Anti-Human Protein Gene Product 9.5 (1:10 000; Ultraclone, Isle of Man, UK) at 4 °C. Sections were then processed to reveal immunoreactivity using the avidin-biotin complex peroxidase method. Briefl y, sections were incubated for 1 h with a biotinylated goat anti-rabbit antibody (sc-2018, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then for 30 min in the avidin/biotinylated-HRP complex at room temperature. Peroxidase activity was visualized using the diaminobenzidine system. Sections were then counterstained with eosin or hematoxylin, dehydrated, cleaned in Bioclear tissue clearing agent (EMS, Hatfi eld, PA, USA) and mounted with Eukitt ® mounting medium (EMS, Hatfi eld, PA, USA). IENFD was evaluated throughout the whole length of the skin sample in a blinded fashion, and was expressed as number of IENF/mm 2 skin.
Poly(ADP-ribose) immunoreactivity analysis in sciatic nerves
On day 41 right sciatic nerves were collected from 3 rats per group, fi xed in 4 % paraformaldehyde and subsequently prepared for cryosectioning (30 % sucrose/PBS at 4 °C for 24 h, Tissue-Tek ® OCT ™ Compound at room temperature for 24 h).
Longitudinal sections (10 μm) were cut with a Leica CM3050 S cryostat and mounted on Superfrost Ultra Plus ® glass slides (Menzel, Braunschweig, Germany). Sections were washed with 0.1 % Tween-20/PBS and subjected to trypsin antigen retrieval (0.05 % trypsin in 7 mM CaCl 2 for 20 min at 37 °C). Slides were blocked with 5 % normal goat serum and 1 % bovine serum albumin in PBS for 1 h before mouse monoclonal anti-poly(ADPribose) antibody (1:500 in 1 % BSA/PBS; Millipore, Schwalbach/ Ts., Germany) was applied overnight at 4 °C. Samples were washed and incubated with Cy3-labelled goat anti-mouse antibody (1:300 in 1 % BSA/PBS; Dianova, Hamburg, Germany 
Statistical analysis
Analyses of variance (ANOVA) were performed. Fisher's protected least signifi cant diff erence (PLSD) was used for pair-wise comparisons; p-values ≤ 0.05 were considered signifi cant.
Results are presented as means ± standard error of the mean (SEM). Per cent drug-induced reversions of SNCV defi cit or IENF loss were calculated by setting the respective response of the Control/Saline group (non-diabetic rats) as 100 %.
Results

▼ Characterization of diabetic rats
Following STZ administration, body weight and glycemic status were monitored throughout the study. As shown in • ▶ Fig. 1 , a marked growth arrest was observed in STZ-diabetic rats compared with normal growth in non-diabetic (Control/Saline) rats. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. hyperglycemia persisted during the whole length of the study, and treatment with the test compounds did not induce major changes. The reason for the marked decline in blood glucose levels at day 7 in all treatment groups is unclear but could potentially be due to a compensatory enhanced insulin release of the dying β-cells.
SNCV
As shown in • ▶ Fig. 3 and in • ▶ Table 1 , SNCV values in all STZtreated rats at day 10 were reduced by ~35 % compared with non-diabetic control animals. In STZ/Saline-treated rats, SNCV values remained at reduced levels relative to control rats throughout the study. However, in STZ-diabetic rats treatment with the two doses of Actovegin , relative to control rats. A similar dose-dependent improvement in SNCV was also evident at day 39. Prophylactic treatment with the positive control NAC produced a signifi cant (p < 0.05) but slightly less pronounced reversion of SNCV decline at day 25, reaching 82 % relative to control animals. At day 39, however, the SNCV of NAC-treated rats was not signifi cantly different from the STZ/Saline group.
IENFD
STZ/Saline-treated rats showed a marked decrease (32 %) in IENFD compared with non-diabetic rats at the end of the study 
Poly(ADP-ribose) analysis
Sciatic nerves of STZ/Saline-treated rats showed a ~2-fold increase in poly(ADP-ribose) content compared with nondiabetic rats. Treatment with 600 mg/kg Actovegin ® brought poly(ADP-ribose) content back to levels comparable with nondiabetic animals ( • ▶ Fig. 6 ). Conversely, treatment of STZ-dia- Discussion ▼
The present study was performed to elucidate the possible cellular eff ects standing behind the benefi cial eff ects of Actovegin ® recently observed in a clinical trial with patients having chronic diabetic sensorimotor distal symmetric polyneuropathy (DPN; Ziegler et al. 2009 ). Investigations were conducted on streptozotocin (STZ)-induced diabetic related neuropathy in immature rats. The rats in the present study rapidly developed massive hyperglycemia, weight loss and polydipsia after STZ-treatment. These changes were followed by symptomatic neuropathy after 10 days, which was confi rmed by measurement of impaired sensory nerve conduction velocity (SCNV), as well as by reduction of the density of intra-epidermal nerve fi bres (IENF) in the rat skin. Two doses of Actovegin ® were administered intra-peritoneally with the lower dose being equivalent to the dose used to treat DPN patients. The treatment approach chosen in the present study was understood as curative to address the neuropathic symptoms of diabetic rats. We found that Actovegin ® did 
